Transgenic expression of a truncated p100 protein led to the development of B-cell lymphomas in mice, thus demonstrating the oncogenic potential of Nfkb2 mutations [18]. The gene discussed is NFKB2; the disease is B-cell non-Hodgkin lymphoma.